Merck has announced that the FDA has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous… read more.
The development and testing of personalised, multidrug tablets will be one of the outputs of a new research collaboration between Gustave Roussy and FabRx Ltd, a biotechnology start-up… read more.
Merck announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for Keytruda for the treatment of patients with recurrent locally advanced or metastatic gastric… read more.
The Bone and Joint Journal Early mobilisation after hip fracture surgery has become standard care on the basis of national guidance. The evidence for this is based on… read more.
Lupin Pharmaceuticals announced that the FDA has approved the company’s supplemental New Drug Application (sNDA) to expand the use of Solosec (secnidazole) to include the treatment of trichomoniasis… read more.
Journal of Clinical Investigation The discovery that multiciliated cells in the nasal epithelium are the first cells to be targeted in early COVID-19 infection might provide the rationale… read more.
Royal Philips announced FDA 510k-clearance of real-time 3D intracardiac echocardiography (ICE) VeriSight Pro catheter which has the potential to improve standard of care for structural heart disease and… read more.
A new study of Soliqua (insulin glargine 100 Units/mL and lixisenatide, (iGlarLixi) met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed… read more.
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency will update the Dupixent (dupilumab) summary of product characteristics (SmPC) adding long-term safety results for adults with… read more.
Scientists isolated a molecule, extracted from the leaves of the European chestnut tree, with the power to neutralize dangerous, drug-resistant staph bacteria. Frontiers in Pharmacology published the finding, led by… read more.
AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes… read more.
The oldest strain of Yersinia pestis–the bacteria behind the plague that caused the Black Death, which may have killed as much as half of Europe’s population in the 1300s–has… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
